In the era of potent TKI therapy the importance of regular high-quality molecular monitoring is more important than ever in patients with chronic myeloid leukaemia (CML), Australian haematologists say. The availability of potent TKI agents that achieve good long-term disease control should not lull clinicians into a false sense of complacency about the need to monitor ...
No room for complacency on molecular monitoring in CML
By Michael Woodhead
28 Nov 2018